Cantor Fitzgerald Reiterates Buy Rating for Theravance Biopharma (TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued on Friday. They presently have a $55.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 113.10% from the company’s previous close.

The analysts wrote, “We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its four key programs (JAK Inhibitor, NEP Inhibitors, TD-9855, Revefenacin), all of which have data expected this year. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. Our DCF analysis arrives at a 12-month share price of $60.””

TBPH has been the subject of several other research reports. ValuEngine lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Leerink Swann set a $38.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, August 1st. BidaskClub lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $47.00.

Theravance Biopharma stock opened at $25.81 on Friday. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. Theravance Biopharma has a 52-week low of $21.27 and a 52-week high of $35.48. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -4.74 and a beta of 2.09.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.08. The firm had revenue of $12.84 million during the quarter, compared to analyst estimates of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 355.48%. Analysts forecast that Theravance Biopharma will post -4.26 earnings per share for the current year.

In related news, CFO Renee D. Gala sold 43,743 shares of Theravance Biopharma stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $26.79, for a total value of $1,171,874.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Bradford J. Shafer sold 7,119 shares of Theravance Biopharma stock in a transaction on Monday, August 27th. The shares were sold at an average price of $27.71, for a total transaction of $197,267.49. Following the completion of the sale, the executive vice president now directly owns 84,000 shares of the company’s stock, valued at approximately $2,327,640. The disclosure for this sale can be found here. In the last three months, insiders sold 57,255 shares of company stock valued at $1,551,343. 6.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in shares of Theravance Biopharma by 2.2% during the third quarter. BlackRock Inc. now owns 3,833,409 shares of the biopharmaceutical company’s stock valued at $125,239,000 after buying an additional 82,620 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in shares of Theravance Biopharma during the third quarter worth about $8,321,000. Engineers Gate Manager LP purchased a new position in shares of Theravance Biopharma during the third quarter worth about $662,000. Alps Advisors Inc. grew its holdings in shares of Theravance Biopharma by 22.5% during the third quarter. Alps Advisors Inc. now owns 97,513 shares of the biopharmaceutical company’s stock worth $3,186,000 after purchasing an additional 17,906 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new position in shares of Theravance Biopharma during the third quarter worth about $285,000. 84.74% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Featured Article: What Factors Can Affect Return on Equity?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply